Literature DB >> 3146224

Side effects of valproate.

F E Dreifuss1, D H Langer.   

Abstract

In the management of epilepsy, selecting an antiepileptic drug appropriate for each individual patient requires matching the patient's clinical needs with the agent's specific pharmacologic attributes. In many situations, the final choice of an antiepileptic drug is based upon an agent's side-effect profile. Because side-effect profiles emerge gradually as the number of patients treated expands from the thousands to the hundreds of thousands, it is helpful to periodically update our perspective of side effects of antiepileptic drugs. For valproate, the frequency of side effects has been reduced by monitoring serum levels, using improved formulations, and limiting use in patients who have been identified as having a high risk for the development of a serious side effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146224     DOI: 10.1016/0002-9343(88)90055-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

1.  Anticonvulsant-induced rickets and nephrocalcinosis.

Authors:  Keith K Lau; Koyelle Papneja
Journal:  BMJ Case Rep       Date:  2012-02-25

2.  Fatal pancytopenia during high-dose valproate monotherapy.

Authors:  J Rajantie; M Kajosaari; V Ylitalo
Journal:  Eur J Pediatr       Date:  1992-08       Impact factor: 3.183

3.  Autoimmune haemolytic anaemia and renal Fanconi syndrome caused by valproate therapy.

Authors:  Toru Watanabe; Kosuke Nakayasu; Yoshihisa Nagayama
Journal:  Eur J Pediatr       Date:  2004-12-10       Impact factor: 3.183

4.  Gingival hyperplasia due to sodium valproate.

Authors:  M Behari
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-03       Impact factor: 10.154

5.  Secondary renal Fanconi syndrome caused by valproate therapy.

Authors:  Toru Watanabe; Hideto Yoshikawa; Sawako Yamazaki; Yuki Abe; Tokinari Abe
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

6.  Vitamin U has a protective effect on valproic acid-induced renal damage due to its anti-oxidant, anti-inflammatory, and anti-fibrotic properties.

Authors:  Selda Gezginci-Oktayoglu; Ismet Burcu Turkyilmaz; Merve Ercin; Refiye Yanardag; Sehnaz Bolkent
Journal:  Protoplasma       Date:  2015-03-24       Impact factor: 3.356

7.  Haematological disturbances during long-term valproate therapy.

Authors:  B Brichard; C Vermylen; J M Scheiff; J Ninane; G Cornu
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

Review 8.  Inositol depletion, GSK3 inhibition and bipolar disorder.

Authors:  Wenxi Yu; Miriam L Greenberg
Journal:  Future Neurol       Date:  2016-04-26

9.  Valproate encephalopathy and hypocarnitinaemia in diabetic patients.

Authors:  L Averbuch-Heller; T Ben-Hur; A Reches
Journal:  J Neurol       Date:  1994-08       Impact factor: 4.849

10.  Restoration of Megalin-Mediated Clearance of Alveolar Protein as a Novel Therapeutic Approach for Acute Lung Injury.

Authors:  Christine U Vohwinkel; Yasmin Buchäckert; Hamza M Al-Tamari; Luciana C Mazzocchi; Holger K Eltzschig; Konstantin Mayer; Rory E Morty; Susanne Herold; Werner Seeger; Soni S Pullamsetti; István Vadász
Journal:  Am J Respir Cell Mol Biol       Date:  2017-11       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.